Steven Keith Burke is VP at Akebia Therapeutics, Inc. (AKBA). They have made 13 open-market trades across 2 companies since 2017, most recently 2026-09-18.
CIK 0001619834
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $119K since 2017, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKBA | SELL · 10b5-1 | 2026-02-02 | 2026-02-04 | $1.39 | $94K | -11.8% | -6.6% | +7.0% |
| AKBA | SELL · 10b5-1 | 2025-03-03 | 2025-03-04 | $1.83 | $13K | +24.2% | +3.3% | +78.6% |
| AKBA | SELL · 10b5-1 | 2025-02-03 | 2025-02-04 | $2.10 | $163K | -0.9% | -10.7% | +8.8% |
| AKBA | SELL | 2024-02-29 | 2024-03-01 | $1.58 | $11K | -20.3% | -7.9% | -39.0% |
| AKBA | SELL · 10b5-1 | 2024-02-27 | 2024-02-29 | $1.52 | $13K | -9.6% | +3.8% | -34.4% |
| AKBA | SELL | 2024-02-01 | 2024-02-02 | $1.68 | $41K | -7.3% | -1.8% | -21.2% |
| AKBA | SELL | 2023-08-25 | 2024-05-09 | $1.15 | $31K | -9.6% | -12.8% | -11.2% |
| AKBA | SELL | 2023-05-16 | 2023-05-18 | $1.07 | $136K | -3.7% | +4.6% | +16.7% |
| AKBA | SELL | 2023-03-01 | 2023-03-03 | $0.88 | $12K | -30.0% | -39.8% | +13.6% |
| AKBA | SELL | 2023-02-27 | 2023-03-01 | $0.81 | $6K | -12.2% | -34.8% | +11.5% |
| AKBA | SELL | 2022-08-31 | 2022-09-01 | $0.36 | $413 | +1.4% | -16.4% | -28.0% |
| AKBA | SELL | 2022-02-28 | 2022-03-02 | $2.16 | $33K | -3.2% | -73.0% | -85.0% |
| AKBA | SELL | 2021-08-31 | 2021-09-02 | $2.83 | $3K | -10.0% | -9.4% | -16.8% |
| AKBA | SELL | 2021-04-01 | 2021-04-01 | $3.40 | $4K | -7.3% | -5.4% | +12.8% |
| AKBA | SELL | 2021-03-01 | 2021-03-02 | $3.40 | $26K | +3.5% | -4.5% | -2.2% |
| AKBA | BUY | 2019-11-20 | 2019-11-22 | $3.58 | $97K | +44.6% | +57.8% | +144.4% |
| PRTO | BUY | 2017-12-15 | 2017-12-18 | $1.88 | $23K | +2.7% | +54.1% | +29.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.